32 reports

  • 4.1.1 ETIOLOGY
  • 5.7.1 EPIDEMIOLOGICAL FORECAST INSIGHT

Oral Contraceptive and Cancer Risks.

  • Breast Cancer
  • Colorectal Cancer
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 2.3 Etiology
  • 9.3 Bibliography

Oral contraceptives and breast cancer risk in Taiwan, a country of low incidence of breast cancer and low use of oral contraceptives.

  • Breast Cancer
  • Colorectal Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group
  • HUGE MARKET POTENTIAL FOR BREAST CANCER MABS OWING TO PRODUCT APPROVALS

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.

  • Breast Cancer
  • Colorectal Cancer
  • Amgen Inc.
  • Mylan Inc.
  • Roche Group
  • 3.1 ETIOLOGY AND PATHOPHYSIOLOGY

Combination hormone products, such as the estrogen + progestin contraceptive pill, have also been associated with an increased risk of breast cancer (NCI, 2016).

  • Breast Cancer
  • Colorectal Cancer
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • 2.1.2 Causes of Breast Cancer

The Aptima HIV-## Quant assay is not approved for HIV-## diagnosis in the United States.

  • Breast Cancer
  • World
  • Business Expansion & Exit
  • Demand
  • Hologic, Inc.
  • Breast Cancer Therapeutics Market, Taiwan, Market Size ($m), 2015-2022
  • Breast Cancer Therapeutics, South Korea, Age-Specific Incidence (%), 2012

Oral contraceptives and breast cancer risk in Taiwan, a country of low Journal of the National Cancer incidence of breast cancer and low use of oral contraceptives.

  • Breast Cancer
  • Colorectal Cancer
  • Market Size
  • Genentech, Inc.
  • Novartis AG

For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer.

  • Breast Cancer
  • Colorectal Cancer
  • World
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • 2.7.1 Epidemiological Forecast Insight

Chronic Diseases and Translational Medicine; ##(##): ##-##.

  • Breast Cancer
  • China
  • Japan
  • United States
  • Forecast

These include oral contraceptive use, multiple pregnancies and prolonged lactation.

  • Breast Cancer
  • Colorectal Cancer
  • Market Size
  • Celgene Corporation
  • Merck & Co., Inc.

The magnitude of the impact has been categorized as described below: Low Moderate - Medium-level impact on the market High - Negligible or no impact on the market landscape - Very high impact, with radical influence on the growth of the market ## ## ## ## ## ## ## ## ## ## ## ## ## ## ##

  • Breast Cancer
  • Colorectal Cancer
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • REFERRAL IS DICTATED BY STAGE AT DIAGNOSIS AND ELECTED TREATMENT APPROACH

Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, et al. (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer.

  • Breast Cancer
  • Colorectal Cancer
  • European Union
  • Japan
  • United States
  • 2.3 ETIOLOGY

Combination hormone products, such as the estrogen and progestin contraceptive pill, have also been associated with an increased risk of breast cancer (NCI, 2013).

  • Breast Cancer
  • Colorectal Cancer
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Quartette is an oral contraceptive indicated for the prevention of pregnancy.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • NOV 14, 2017: FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB
  • DEC 06, 2017: H3 BIOMEDICINE PRESENTS PRECLINICAL DATA ON NOVEL ERA ANTAGONIST AT SAN ANTONIO BREAST CANCER SYMPOSIUM

We believe that Estelle has the potential to become a true ' next - generation' contraceptive option, including in North America, a market worth ##% of the USD ##bn worldwide contraceptive market.

  • Breast Cancer
  • Hormone
  • Hospital
  • Product Initiative
  • Mithra
  • 14. Market Growth Drivers

The use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing the disease.

  • Breast Cancer
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.
  • (ER+) breast cancer. The trial was registered with the U.S. National Institutes of Health.

Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises ##, ## and ## molecules, respectively.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • Medical Care 12%

Its highest selling products include Betaferon/ Betaseron (multiple sclerosis); YAZ/ Yasmin/ Yasminelle (hormonal contraceptive); Kogenate (hemophilia); Nexavar (cancer); Adalat (hypertension); and Mirena (hormonal contraceptive).

  • Breast Cancer
  • Colorectal Cancer
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Sanofi S.A.
  • GLOBAL INCIDENCE OF BREAST CANCER, 2012-2025
  • MARKET DYNAMICS (2/10)

This can majorly be attributed to changing lifestyles, increasing use of oral contraceptives, and the growing number of women undergoing cosmetic surgeries such as breast enhancement.

  • Breast Cancer
  • North America
  • United States
  • Forecast
  • Cianna Medical, Inc.

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/ CTA Filed and Preclinical stages are ##, ##, ##, ##, ## and ## respectively.

  • Breast Cancer
  • Colorectal Cancer
  • HIV AIDS
  • Therapy
  • CytoDyn Inc.

Quartette is an oral contraceptive indicated for the prevention of pregnancy.

  • Breast Cancer
  • Hormone
  • United States
  • World
  • Product Initiative
  • 10.2 PARENTERAL

Use of birth control contraceptives and hormonal therapy after menopause increase the risk for developing breast cancer as they contain synthetic sex hormones.

  • Breast Cancer
  • United States
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

The prominent features of this report are - ##.

  • Breast Cancer
  • Cancer
  • Colorectal Cancer
  • World
  • Novartis AG

Patients were randomized into one of four arms (mirogabalin ## mg once-daily, mirogabalin ## mg twice-daily, mirogabalin ## mg twice-daily or placebo) at the ratio of ##:##:##:##, respectively.

  • Breast Cancer
  • Colorectal Cancer
  • Japan
  • United States
  • Daiichi Sankyo Company
  • 4.4.2 Genetics
  • 4.3 DIAGNOSIS

Higher estrogen levels can be associated with the use of hormone replacement therapy and oral contraceptives (Institute of Medicine Committee, 1991).

  • Breast Cancer
  • Cancer
  • Colorectal Cancer
  • Pathology
  • Therapy

It acts as inhibitor of mitogen activated protein Kinase-##/ ## (MEK ##/ ##).

  • Breast Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • Therapy
  • Novartis AG

GlaxoSmithKline registered a Phase I open-label, non-randomized, sequential, two-period, repeat-dose study to evaluate the pharmacokinetics and safety of trametinib on combined oral contraceptive (norethindrone plus ethinyl estradiol) in female subjects with solid tumors.

  • Breast Cancer
  • Colorectal Cancer
  • Targeted Therapy
  • Therapy
  • Novartis AG

Median follow-up was ## ## months (IQR ## ##-## ##).

  • Breast Cancer
  • Cancer
  • Colorectal Cancer
  • United States
  • Company Operations
  • COLORECTAL CANCER - PIPELINE BY KURA ONCOLOGY INC
  • COLORECTAL CANCER - PIPELINE BY LABORATORIO ELEA SACIF Y A

IT ALSO OFFERS PRODUCTS FOR THERAPEUTIC AREAS SUCH AS HIPOLIPEMIANTES, ANTIBIOTICOS, AIDS, BONE CALCIUM REGULATORS, FERTILITY, HORMONE THERAPY, LAXATIVES, PARKINSON' S DISEASE, CONTRACEPTIVES, AND ANTIVIRAL, AMONG OTHERS.

  • Breast Cancer
  • Colorectal Cancer
  • Therapy
  • Product Initiative
  • Merck & Co., Inc.

ASTRAZENECA REGISTERED A PHASE I SINGLE-BLIND, PLACEBO-CONTROLLED, ##-PERIOD, FIXED SEQUENCE STUDY TO EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF COADMINISTRATION OF FOSTAMATINIB ## MG TWICE DAILY ON THE PHARMACOKINETICS OF AN ORAL CONTRACEPTIVE IN HEALTHY FEMALE SUBJECTS.

  • Breast Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Therapy
  • Merck & Co., Inc.

GLAXOSMITHKLINE REGISTERED A PHASE I OPEN-LABEL, NON-RANDOMIZED, SEQUENTIAL, TWO-PERIOD, REPEAT-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF TRAMETINIB ON COMBINED ORAL CONTRACEPTIVE (NORETHINDRONE PLUS ETHINYL ESTRADIOL) IN FEMALE SUBJECTS WITH SOLID TUMORS.

  • Breast Cancer
  • Cell Therapy
  • Colorectal Cancer
  • United States
  • Company